Alzheimer’s diagnostics are undergoing one of the most significant transformations in decades. What once required PET imaging or invasive CSF collection is rapidly moving toward simple blood‑based assays powered by ultrasensitive detection of core biomarkers: pTau, Aβ42/40, GFAP, and NfL.
This shift isn’t just about convenience. It’s about accessibility, scalability, and earlier detection—the three pillars that will define the next generation of neurodegenerative disease research and clinical care.
As these minimally invasive approaches gain momentum, the scientific community needs tools that are accurate, reproducible, and translationally relevant. That’s exactly where VexisBio’s portfolio aligns with the field’s trajectory.

• Precision ELISAs for the biomarkers driving the new diagnostic era
  Blood‑based diagnostics depend on assays that can reliably quantify low‑abundance proteins in complex matrices. VexisBio’s ELISA kits for pTau181, pTau217, Aβ1‑42, Aβ1‑40, GFAP, and NfL support researchers who are validating these markers in serum and plasma—exactly the matrices shaping clinical adoption.
• Recombinant proteins and calibrators that enable standardization
  As diagnostic platforms evolve, so does the need for high‑purity standards and well‑characterized controls. VexisBio’s recombinant Tau, phospho‑Tau, Aβ peptides, and neurodegeneration markers help labs build assays that are not only sensitive but also traceable and comparable across studies.
• Antibody pairs optimized for low‑volume, high‑sensitivity workflows
  Minimally invasive diagnostics demand assays that work with tiny sample volumes without compromising performance. VexisBio’s antibody pairs are selected and validated with this requirement in mind, supporting both traditional ELISA and next‑generation platforms.
• Supporting the transition from discovery to translation

The field is moving toward multi‑analyte panels that combine amyloid, tau, neurodegeneration, and astrocyte activation markers. VexisBio’s catalog already mirrors this structure, enabling researchers to build and validate the same biomarker combinations now appearing in clinical trials and regulatory submissions.

🧠 The takeaway
The rise of blood‑based Alzheimer’s diagnostics isn’t a distant future—it’s happening now. And the labs driving this shift need tools that are sensitive, reliable, and built for translational workflows.
VexisBio is uniquely positioned to support this evolution, providing the reagents and assay systems that make minimally invasive diagnostics not only possible but practical.